Arxis Securities’s Cellectar Biosciences CLRB Stock Holding History

Arxis Securities’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5	Closed	-$20K	–	47
2016 Q4	$20K	Buy	+5	New	+$27.1K	0.03%	50

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

WAM

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Arxis Securities's CLRB Position: Q1 2017 in Review

Arxis Securities sold out of Cellectar Biosciences (CLRB) in Q1 2017, closing a stake of 5 shares — an estimated $20K sold.

Arxis Securities first reported a position in CLRB in Q4 2016 and held it in 1 quarter. The position peaked at $20K in Q4 2016. 9 funds tracked by Wall St. Rank hold CLRB as of Q1 2017.

Arxis Securities reported no remaining Cellectar Biosciences position as of Q1 2017 after selling out during the quarter.
Arxis Securities sold 5 Cellectar Biosciences shares in Q1 2017, an estimated $20K.
Arxis Securities first reported a position in Cellectar Biosciences in Q4 2016 and held it in 1 quarter.
Arxis Securities's Cellectar Biosciences position peaked at $20K in Q4 2016.
9 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2017.

Based on Arxis Securities's 13F filing for Q1 2017, filed 8 May 2017.